High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia

Area of Science:

• Pediatric Hematology
• Immunosuppressive Therapy
• Aplastic Anemia Research

Background:

• High-dose cyclophosphamide (HDC) use in severe aplastic anemia (SAA) is debated due to infectious toxicity concerns.
• Pediatric patients may tolerate intensive therapies better than adults, warranting specific investigation.

Purpose of the Study:

• To evaluate treatment response and toxicity of HDC as sole immunosuppression in pediatric SAA patients.
• To compare outcomes of HDC in children and adolescents with SAA to existing treatment modalities.

Main Methods:

• Retrospective analysis of 28 pediatric patients (<22 years) receiving 29 courses of HDC.
• Treatment involved cyclophosphamide (50 mg/kg/d for 4 days), G-CSF, transfusions, and antimicrobial prophylaxis.

Main Results:

• Overall survival reached 85%, with 79% hematologic response and 66% complete response.
• High rates of bacterial (86%) and fungal (62%) infections were observed, but infection-related deaths were rare.
• Low rates of clonal evolution (1/28), paroxysmal nocturnal hemoglobinuria (1/28), and relapse (2/28) were noted.

Conclusions:

• HDC in pediatric SAA yields superior response rates and survival compared to adult data.
• Outcomes compare favorably to antithymocyte globulin/cyclosporine A, with manageable infectious toxicity.